Sign inCreate account

Report workspace tools

NCT02992496UNKNOWNanonymous

Investigation of Antidepressant Efficacy of Oral Ketamine Treatment

Sponsor

Source record

Medical University of Vienna

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Ketamine, Midazolam Hydrochloride

Indication / condition

AI-normalized

Major Depressive Episode

Intervention

Source record

Ketamine, Midazolam Hydrochloride

Source & freshness

Source record

NCT ID

NCT02992496

Original source

ClinicalTrials.gov

Source last updated

Sep 03, 2019

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02992496

Title

Investigation of Antidepressant Efficacy of Oral Ketamine Treatment

Sponsor

Medical University of Vienna

Status

UNKNOWN

Phase

PHASE2

Condition raw

Major Depressive Episode

Condition normalized

Major Depressive Episode

Modality raw

major depressive disorder

Modality normalized

small molecule

Target raw

Ketamine, Midazolam Hydrochloride

Target normalized

Ketamine, Midazolam Hydrochloride

Interventions

Ketamine, Midazolam Hydrochloride

Public preview

Source record

Investigation of Antidepressant Efficacy of Oral Ketamine Treatment is a PHASE2 clinical asset sponsored by Medical University of Vienna in Major Depressive Episode. SEO and diligence focus: Ketamine, Midazolam Hydrochloride, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Investigation of Antidepressant Efficacy of Oral Ketamine Treatment

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02992496

Status

UNKNOWN

Phase

PHASE2

Sponsor

Medical University of Vienna

Executive brief

Investment-Ready Snapshot

Investigation of Antidepressant Efficacy of Oral Ketamine Treatment is a PHASE2 clinical asset sponsored by Medical University of Vienna in Major Depressive Episode. SEO and diligence focus: Ketamine, Midazolam Hydrochloride, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 03, 2019
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02992496

Indication

Major Depressive Episode

Modality

small molecule

Target

Ketamine, Midazolam Hydrochloride

Intervention

Ketamine, Midazolam Hydrochloride

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.